** Shares of drug developer Zentalis Pharmaceuticals ZNTL.O fall ~19% to $1.94
** ZNTL says its experimental cancer drug, azenosertib, works better than current treatments in ovarian cancer patients who have previously been treated with platinum-based chemotherapy and whose cancer has become resistant
** It reported data from two mid-stage trials testing its therapy alone or in combination with niraparib in patients with ovarian cancer and platinum-resistant ovarian cancer patients
** In one of the studies, ZNTL's drug resulted in a 5.5 months duration of response on average in patients
** Oppenheimer analyst Matthew Biegler says investors are "squabbling" as the duration of response was slightly under 6 months, a pivotal study could take another 2 years and that accelerated approval isn't a "done deal"
** Wedbush analyst Robert Driscoll says he remains "unconvinced" by the durability data that will ultimately support full approval
** ZNTL is seeking the U.S. FDA's accelerated approval for its drug to treat platinum-resistant ovarian cancer
** ZNTL fell ~81% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.